Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis: A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases provides a detailed investigation into tryptamine, its underlying mechanisms, and metabolism across multiple diseases. The book explores key concepts of tryptamine, its biosynthetic pathways, and its influence in disease, specifically focusing on the Alzheimer’s disease-associated gut bacterial sequence (ADAS). Various neurodegenerative conditions are covered alongside cancer, diabetes, infections, and chromosomal aberrations. Additionally, a chapter on gut tryptamine in domestic and agricultural animals is included. The book closes with case studies involving FDG-PET imaging in the context of tryptamine-treated mouse models and Alzheimer’s disease patients.
This book elucidates the implications of the gut microbiota-mediated tryptamine metabolism for human health, sharing insights into disease etiology, mechanisms, testing, prevention, and treatment. It is an ideal reference for researchers across the biomedical sciences.
1. Chapter 1 Introduction - p. 2 2. Chapter 2 Human gut microbial metabolite tryptamine inducing neurodegeneration causes chromosome and genome instability - p. 38 3. Chapter 3 Mutagenicity and genotoxicity of naturally occurring tryptamines and their principal metabolites - p. 70 4. Chapter 4 Abundant urinary tryptamine as an indicator of urinary tract infection and nosocomial infections - p. 82 5. Chapter 5 Proteus mirabilis, diseases, and tryptamine - p. 92 6. Chapter 6 Microbial tryptophan metabolites in cancer and leishmaniasis - p. 106 7. Chapter 7 The effect of human microbial metabolome on multisensory integration in aging and neurodegenerative diseases - p. 122 8. Chapter 8 Retinitis pigmentosa (RP): RP-causative gene mutations, RP-related gene mutations, mosaicism, and gut microbiome - p. 148 9. Chapter 9 The tRNA aminoacylation interference in diseases - p. 166 10. Chapter 10 Tryptamine interfere with cytochrome P450 - p. 178 11. Chapter 11 Discovery of Alzheimer's disease-associated sequence and Caudoviricetes prophage markers in metagenomics of type 2 diabetes and associated medical conditions - p. 190 12. Chapter 12 Tryptamine, ADAS and microbiome in Parkinson's disease - p. 206 13. Chapter 13 Microbial ADAS and tryptamine in domestic and agricultural animals - p. 222 14. Chapter 14 Tryptamine, stem cell/progenitor protein biosynthesis, and aminoacyl-tRNA biosynthesis - p. 233 15. Chapter 15 Tryptamine metabolite indole-3-acetic acid in neurodegenerative diseases and other conditions - p. 246 16. Chapter 16 FDG-PET: Tryptamine-treated mouse model and Alzheimer's disease patients. Conceptual evolution of microbiota tryptamine role in human diseases - p. 254 17. Chapter 17 Epilepsy, tryptamine-induced seizures, malfunction of ion channels, electrolyte abnormalities and antibiotic resistance - p. 270 18. Chapter 18 Conclusions - p. 288 19. Index - p. 293
Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis: A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases provides a detailed investigation into tryptamine, its underlying mechanisms, and metabolism across multiple diseases. The book explores key concepts of tryptamine, its biosynthetic pathways, and its influence in disease, specifically focusing on the Alzheimer’s disease-associated gut bacterial sequence (ADAS). Various neurodegenerative conditions are covered alongside cancer, diabetes, infections, and chromosomal aberrations. Additionally, a chapter on gut tryptamine in domestic and agricultural animals is included. The book closes with case studies involving FDG-PET imaging in the context of tryptamine-treated mouse models and Alzheimer’s disease patients.
This book elucidates the implications of the gut microbiota-mediated tryptamine metabolism for human health, sharing insights into disease etiology, mechanisms, testing, prevention, and treatment. It is an ideal reference for researchers across the biomedical sciences.
1. Chapter 1 Introduction - p. 2 2. Chapter 2 Human gut microbial metabolite tryptamine inducing neurodegeneration causes chromosome and genome instability - p. 38 3. Chapter 3 Mutagenicity and genotoxicity of naturally occurring tryptamines and their principal metabolites - p. 70 4. Chapter 4 Abundant urinary tryptamine as an indicator of urinary tract infection and nosocomial infections - p. 82 5. Chapter 5 Proteus mirabilis, diseases, and tryptamine - p. 92 6. Chapter 6 Microbial tryptophan metabolites in cancer and leishmaniasis - p. 106 7. Chapter 7 The effect of human microbial metabolome on multisensory integration in aging and neurodegenerative diseases - p. 122 8. Chapter 8 Retinitis pigmentosa (RP): RP-causative gene mutations, RP-related gene mutations, mosaicism, and gut microbiome - p. 148 9. Chapter 9 The tRNA aminoacylation interference in diseases - p. 166 10. Chapter 10 Tryptamine interfere with cytochrome P450 - p. 178 11. Chapter 11 Discovery of Alzheimer's disease-associated sequence and Caudoviricetes prophage markers in metagenomics of type 2 diabetes and associated medical conditions - p. 190 12. Chapter 12 Tryptamine, ADAS and microbiome in Parkinson's disease - p. 206 13. Chapter 13 Microbial ADAS and tryptamine in domestic and agricultural animals - p. 222 14. Chapter 14 Tryptamine, stem cell/progenitor protein biosynthesis, and aminoacyl-tRNA biosynthesis - p. 233 15. Chapter 15 Tryptamine metabolite indole-3-acetic acid in neurodegenerative diseases and other conditions - p. 246 16. Chapter 16 FDG-PET: Tryptamine-treated mouse model and Alzheimer's disease patients. Conceptual evolution of microbiota tryptamine role in human diseases - p. 254 17. Chapter 17 Epilepsy, tryptamine-induced seizures, malfunction of ion channels, electrolyte abnormalities and antibiotic resistance - p. 270 18. Chapter 18 Conclusions - p. 288 19. Index - p. 293
